Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma

被引:33
|
作者
Oh, Sung Yong
Ryoo, Baek-Yeol
Kim, Won Seog
Kim, Kihyun
Lee, Jeeyun
Kim, Hyun Jung
Kwon, Jung Mi
Lee, Hyo Rak
Ko, Young Hye
Oh, Suk Joong
Park, Keon Woo
Kim, Hyo-Jin
Kwon, Hyuk-Chan
Nam, Eunmi
Kim, Jung Han
Park, Yeon Hee
Lee, Seung-Sook
Kim, Ho Young
Park, Keunchil
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol & Oncol, Seoul 135710, South Korea
[2] Samsung Med Ctr, Dept Pathol, Seoul 135710, South Korea
[3] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Internal Med, Seoul 135710, South Korea
[4] Dankook Univ, Coll Med, Dept Internal Med, Cheonan, South Korea
[5] Dong A Univ, Coll Med, Dept Internal Med, Pusan, South Korea
[6] Inje Univ, Sanggye Pk Hosp, Coll Med, Dept Internal Med, Seoul, South Korea
[7] Gachon Med Sch, Dept Internal Med, Inchon, South Korea
[8] Hallym Univ, Coll Med, Dept Internal Med, Chunchon, South Korea
[9] Korea Inst Radiol & Med Sci, Dept Hematol & Oncol, Seoul, South Korea
[10] Korea Inst Radiol & Med Sci, Dept Pathol, Seoul, South Korea
[11] Yonsei Univ, Wonju Coll Med, Dept Internal Med, Wonju, South Korea
关键词
nodal; marginal zone B-cell lymphoma;
D O I
10.1007/s00277-006-0160-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nodal marginal zone B-cell lymphoma (NMZL) is a relatively uncommon type of lymphoma. Because of the rarity, the natural history and the optimal treatment modality have not been well defined. Therefore, we performed a retrospective analysis of the clinical features and treatment outcomes of NMZL. Thirty-six patients who were histologically diagnosed as NMZL were included in the analysis. Fifty-three percent of the patients had localized disease (stages I and II), and 21.2% (7/33) had bone marrow involvement at presentation. B symptom was present in only three patients (8.3%). Most patients were categorized as low or low-intermediate risk group by international prognostic index (IPI) (77.1%). Majority (94.4%) of the patients with localized disease achieved complete remission (CR) after the initial treatment. Of the seven patients with disseminated disease, who were treated with anthracycline-based chemotherapy, four patients achieved CR. Of the seven patients who received nonanthracycline-based chemotherapy, no patient achieved CR. After the median follow-up duration of 36 months, the median progression-free survival (PFS) was 3.9 (95% CI; 2.9-5.6) years, and the estimated 5-year PFS and overall survival rates were 47.2 and 82.7%, respectively. The significant predictive factors for PFS were performance status, advanced stage, and follicular lymphoma IPI (FLIPI) in this study. This clinical feature is similar to FL rather than to MZL-MALT type.
引用
收藏
页码:781 / 786
页数:6
相关论文
empty
未找到相关数据